Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Peripheral Nervous System Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Cardiotoxicity 1

Interventions

Everolimus 5Cetuximab 2volagidemab 1tanezumab 1pembrolizumab 1inavolisib 1Vemurafenib 1Trimetazidine 1Sirolimus 1Secretin 1SF 1126 1Pharmaceutical Preparations 1Panobinostat 1Oxaliplatin 1Nivolumab 1NVP-BKM120 1Leucovorin 1Irinotecan 1Fulvestrant 1Fluorouracil 1Drug Therapy 1Capecitabine 1CB-839 1CA-19-9 Antigen 1Bevacizumab 1Aspirin 1Alpelisib 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hereditary Sensory and Autonomic Neuropathies × Trimetazidine × Clear all
NCT06459193 2025-03-30

Trimetazidine Efficacy in Attenuating Paclitaxel-Induced Peripheral Neuropathy

Minia University

Phase 1/2 Completed
60 enrolled

Hereditary Sensory and Autonomic Neuropathies, Peripheral Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡